The Effects of Local Calf Vibration on Balance, Blood Flow, and Nerve Conductivity in Patients With Diabetic Peripheral Neuropathy: A Pilot Study Publisher



Fateh HR^{1, 2} ; Nakhostin Ansari N^{3, 4} ; Nakhostinansari A^{5, 6} ; Sabziparvar M³ ; Naybandi S⁷ ; Naghdi S³ ; Honarpishe R³ Show Affiliations
Source: Physiotherapy Theory and Practice Published:2023

Abstract

Objectives: This study aimed to evaluate the effects of local calf vibration on balance, blood flow, and nerve conductivity in patients with diabetic peripheral neuropathy (DPN). Methods: An open-label controlled trial was designed. Patients with confirmed diagnoses of type 2 diabetes and DPN were enrolled in the study and underwent ten sessions of local calf vibration therapy for the dominant leg. The other leg was considered the control. Balance evaluation, nerve conduction studies, and color Doppler ultrasound were performed before and after the treatment course. The Wilcoxon signed rank test and the Mann–Whitney test were used to evaluate the differences between the test results before and after the intervention and between the intervention and control legs. Results: Seventeen patients with a mean age of 60.3 ± 5.6 years (11 males) participated in the study. Mean Brief BESTest total scores were significantly improved (14.06 vs. 17.35; P = .01, Cohen’s d = 0.743). There were no significant differences between the treated and control legs regarding the nerve conduction and color Doppler ultrasound parameters before and after the intervention (P ≥ .054). Changes in the parameters were also not significantly different between legs (P ≥ .078), except for common peroneal nerve conduction velocity, for which there was a higher increase in its value in the treated legs compared to the control legs (4.17 vs. 0.9, P = .002). Conclusion: Local calf vibration may positively affect balance and lower extremities nerve conduction in patients with DPN, and the findings of this study can be a basis for studies evaluating the efficacy of local calf vibration for treating DPN. © 2023 Taylor & Francis Group, LLC.